LEADER 04206nam 2200673 450 001 9910136793403321 005 20230621140122.0 035 $a(CKB)3710000000631052 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/40269 035 $a(EXLCZ)993710000000631052 100 $a20160411d2016 fy| 0 101 0 $aeng 135 $aurmu#---uuuuu 181 $ctxt$2rdacontent 182 $cc$2rdamedia 182 $ccr$2rdacarrier. 183 $acr$2rdacarrier 200 00$aAdvances in epithelial ovarian cancer$b[electronic resource] $emodel systems, microenvironmental influences, therapy, and origins /$fedited by Viive Maarike Howell, Ben Davidson, Tian-Li Wang and Christina Annunziata 210 $cFrontiers Media SA$d2016 210 1$a[Lausanne, Switzerland] :$cFrontiers Media SA,$d2016. 210 4$dİ2016 215 $a1 online resource (176 pages) $cillustrations; digital, PDF file(s) 225 1 $aFrontiers Research Topics 225 1 $aFrontiers in oncology 311 $a2-88919-769-7 320 $aa Includes bibliographical references. 330 3 $aThis eBook provides a compendium of the current state-of-the-art in research tools for, and understanding of, the critical research areas in epithelial ovarian cancer (EOC) with a strong emphasis on (HG-SOC). Research areas covered include therapy response and development, microenvironmental influences and the etiology and progression of EOC. Ten articles detail established and novel in vivo and in vitro model systems. These include primary and immortalized cell culture in 2D and 3D as well as genetically engineered, transgenic, spontaneous, syngeneic, classical xenograft and patient derived xenograft mouse models. The generation of genetically engineered mouse models of HG-SOC has been a major dilemma as models with the oncogenic aberrations common in the human malignancy do not accurately recapitulate HG-SOC. Conversely, commonly used HG-SOC cell lines have been found to not harbor the expected genetic changes. These issues as well as the rapid acceptance of patient derived xenograft models are reviewed. Five articles discuss different aspects of the tumor microenvironment including its role in therapy resistance, disease progression and metastasis. Mutation of BRCA1/2 continues to be the best defined risk factor for HG-SOC. Three articles discuss BRCA-loss in the context of disease development, targeted therapies and changes in preventative measures proposed for mutation carriers in light of the recent advances in knowledge regarding the origins of this malignancy. An image of HG-SOC with reduced BRCA1 expression is featured on the cover (image by VM Howell). A major clinical issue for patients with HG-SOC is the development of therapy resistance. Five articles focus on therapy resistance and different ways to overcome resistance. Overall, this eBook is an outstanding resource to aid researchers design their programs of research and determine the most appropriate and up-to-date EOC model systems to address their research questions. 410 0$aFrontiers in oncology. 410 0$aFrontiers research topics. 606 $aOvaries$xCancer$xResearch 606 $aNeoplasms 606 $aOncology 610 $a3D-cell culture 610 $aOvarian cancer stem cells 610 $aovarian cancer 610 $atumor-associated macrophage 610 $aBRCA 610 $achemoresistance 610 $afallopian tube 610 $atumour microenvironment 610 $amouse models of ovarian cancer 610 $apatient derived xenografts 610 $aprimary ovarian tumour cells 610 $aAscites 615 0$aOvaries$xCancer$xResearch. 615 0$aNeoplasms. 615 0$aOncology. 676 $a616.99465 700 $aBen Davidson$4auth$01366916 702 $aHowell$b Viive Maarike 702 $aDavidson$b Ben$cM.D., 702 $aWang$b Tian-Li 702 $aAnnunziata$b C$g(Christina) 712 02$aFrontiers Research Foundation, 801 2$bUkMaJRU 906 $aBOOK 912 $a9910136793403321 996 $aAdvances in epithelial ovarian cancer$93389440 997 $aUNINA